# A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD).

> **NCT05919680** · PHASE2 · RECRUITING · sponsor: **NorthSea Therapeutics B.V.** · enrollment: 36 (estimated)

## Conditions studied

- Intestinal Failure Associated Liver Disease

## Interventions

- **DRUG:** NST-6179 Part A
- **DRUG:** NST-6179 Part B
- **OTHER:** Matched Placebo

## Key facts

- **NCT ID:** NCT05919680
- **Lead sponsor:** NorthSea Therapeutics B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-15
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05919680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05919680, "A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD).". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05919680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*